Stock events for Septerna, Inc. (SEPN)
Septerna, Inc. (SEPN) stock has experienced significant positive movement, increasing over 134% and more than 630% from its 52-week low. Key events impacting the stock price include positive Phase 1 data for SEP-631, analyst upgrades and bullish sentiment, presentations at healthcare conferences, and revenue growth. Over the past 90 days, there has been a net sell-off by insiders, with total sell transactions amounting to approximately $2.58 million, and no buy transactions recorded.
Demand Seasonality affecting Septerna, Inc.’s stock price
There is no information available regarding demand seasonality for Septerna, Inc.'s products and services. As a clinical-stage biotechnology company, its current focus is on drug discovery and development, rather than commercial product sales, which typically exhibit seasonality.
Overview of Septerna, Inc.’s business
Septerna, Inc. is a clinical-stage biotechnology company focused on discovering and developing oral small molecule products targeting G protein-coupled receptors (GPCRs). The company operates in the biotechnology industry and utilizes its Native Complex Platform™ to advance drug candidates across multiple therapeutic areas, including the PTH1R Program (SEP-479) for hypoparathyroidism, SEP-631 for mast cell diseases, TSHR Program for Graves' disease and thyroid eye disease, and programs for metabolic disorders, neurology, women's health, cardiovascular disease, and respiratory disease.
SEPN’s Geographic footprint
Septerna, Inc. is headquartered in South San Francisco, California, United States. The information does not detail a broader international geographic footprint for its operations or product distribution at this clinical stage.
SEPN Corporate Image Assessment
Septerna, Inc. has maintained a largely positive brand reputation in the past year, driven by strong analyst confidence and positive sentiment surrounding its drug discovery platform and lead programs. The company's innovative approach to GPCR oral small molecule drug discovery and promising preclinical and Phase 1 clinical trial results for candidates like SEP-631 have contributed to this positive perception.
Ownership
Septerna, Inc. (SEPN) has a significant institutional ownership presence, with 181 institutional owners and shareholders holding a total of 41,326,296 shares, representing approximately 91.2% of the company. Major institutional and individual owners include RA Capital Management, L.P., Driehaus Capital Management Llc, Third Rock Ventures VI, L.P., Samsara BioCapital, LLC, Goldman Sachs Group Inc, Siren, L.L.C., BlackRock, Inc., BVF Inc/il, Vanguard Group Inc, and Avoro Capital Advisors LLC. Third Rock Ventures VI LP is the largest individual Septerna shareholder, owning 10.43 million shares, representing 23.29% of the company.
